Cargando…
Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/ https://www.ncbi.nlm.nih.gov/pubmed/37736358 http://dx.doi.org/10.1016/j.ajpc.2023.100579 |
_version_ | 1785107783589298176 |
---|---|
author | Sukkari, Mohamad Hekmat Al-Bast, Basma Al Tamimi, Raad Giesing, William Siddique, Momin |
author_facet | Sukkari, Mohamad Hekmat Al-Bast, Basma Al Tamimi, Raad Giesing, William Siddique, Momin |
author_sort | Sukkari, Mohamad Hekmat |
collection | PubMed |
description | Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population. |
format | Online Article Text |
id | pubmed-10509658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105096582023-09-21 Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence Sukkari, Mohamad Hekmat Al-Bast, Basma Al Tamimi, Raad Giesing, William Siddique, Momin Am J Prev Cardiol Short Report Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population. Elsevier 2023-09-01 /pmc/articles/PMC10509658/ /pubmed/37736358 http://dx.doi.org/10.1016/j.ajpc.2023.100579 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Short Report Sukkari, Mohamad Hekmat Al-Bast, Basma Al Tamimi, Raad Giesing, William Siddique, Momin Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title_full | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title_fullStr | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title_full_unstemmed | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title_short | Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence |
title_sort | is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated lipoprotein (a)—a review of the evidence |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/ https://www.ncbi.nlm.nih.gov/pubmed/37736358 http://dx.doi.org/10.1016/j.ajpc.2023.100579 |
work_keys_str_mv | AT sukkarimohamadhekmat isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT albastbasma isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT altamimiraad isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT giesingwilliam isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence AT siddiquemomin isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence |